Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Recommendation of “Hold” from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been given an average recommendation of “Hold” by the five analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $67.67.

Several brokerages have commented on PBH. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tidal Investments LLC grew its stake in shares of Prestige Consumer Healthcare by 27.7% in the 2nd quarter. Tidal Investments LLC now owns 39,282 shares of the company’s stock worth $1,857,000 after buying an additional 8,531 shares during the last quarter. Nykredit A S purchased a new position in Prestige Consumer Healthcare during the second quarter valued at $133,000. Corient Private Wealth LP raised its stake in Prestige Consumer Healthcare by 1.3% during the second quarter. Corient Private Wealth LP now owns 25,398 shares of the company’s stock valued at $1,201,000 after buying an additional 331 shares during the last quarter. Amundi raised its stake in Prestige Consumer Healthcare by 51.9% during the second quarter. Amundi now owns 14,052 shares of the company’s stock valued at $664,000 after buying an additional 4,800 shares during the last quarter. Finally, AXQ Capital LP bought a new stake in Prestige Consumer Healthcare in the second quarter worth $572,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Down 0.5%

PBH stock opened at $45.70 on Friday. Prestige Consumer Healthcare has a fifty-two week low of $42.62 and a fifty-two week high of $71.07. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of 12.80, a price-to-earnings-growth ratio of 1.50 and a beta of 0.33. The business’s 50 day moving average price is $50.38 and its two-hundred day moving average price is $51.95. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. During the same quarter last year, the business posted $0.90 EPS. The firm’s revenue for the quarter was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, analysts forecast that Prestige Consumer Healthcare will post 4.56 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc (NYSE: PBH) develops, markets and distributes over-the-counter health care products and household consumer products. Its portfolio includes branded treatments for eye care, gastrointestinal health, women’s health, oral care, respiratory conditions, pain relief and skin care, along with products for lice treatment and motion sickness.

The company’s brands include Clear Eyes, Dramamine, Monistat, Summer’s Eve, Compound W, Chloraseptic, Luden’s, BC, Goody’s, Nix and Hydralyte, among others.